| 22.26 0.24 (1.09%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 30.25 | 1-year : | 35.33 |
| Resists | First : | 25.89 | Second : | 30.25 |
| Pivot price | 21.67  |
|||
| Supports | First : | 20.53 | Second : | 17.21 |
| MAs | MA(5) : | 23.52  |
MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 60.4 | D(3) : | 0 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 25.89 | Low : | 17.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LTGO ] has closed below upper band by 41.8%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 23.78 - 23.9 | 23.9 - 24.02 |
| Low: | 21.06 - 21.17 | 21.17 - 21.29 |
| Close: | 22.08 - 22.26 | 22.26 - 22.44 |
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Wed, 02 Sep 2026
Latigo Biotherapeutics (NASDAQ:LTGO) Upgraded at Leerink Partners - MarketBeat
Wed, 02 Sep 2026
Latigo Biotherapeutics (NASDAQ:LTGO) Stock Rating Upgraded by Guggenheim - MarketBeat
Tue, 01 Sep 2026
Jefferies initiates Latigo Biotherapeutics stock with buy rating - Investing.com
Tue, 01 Sep 2026
Guggenheim initiates Latigo Biotherapeutics stock with buy rating on pain drug potential - Investing.com
Wed, 26 Aug 2026
Latigo Biotherapeutics (LTGO) draws 4.45M-share stake from Deep Track - Stock Titan
Tue, 25 Aug 2026
Foresite funds receive millions of Latigo (LTGO) shares in IPO-linked moves - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 63 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 82.9 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -42.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -103 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -8.8 |
| PEG Ratio | 0 |
| Price to Book value | -0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|